Measles
104
3
4
77
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
30 trials with published results (29%)
Research Maturity
77 completed trials (74% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.9%
3 terminated out of 104 trials
96.3%
+9.7% vs benchmark
54%
56 trials in Phase 3/4
39%
30 of 77 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 77 completed trials
Clinical Trials (104)
Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in Senegal
Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
A Tool Kit to Improve Vaccine Confidence in the Philippines
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
Measles and BCG Vaccines for Mother and Child
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
Co-administration Study of OCV, TCV and MR
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial